Dr. Grudzinskas is a co-Founder of and Partner in NDA Partners and leads the drug division of NDA Partners. Charles Grudzinskas is also a consultant to the Center for Drug Development Science (CDDS), University of California San Francisco at the University of California, Washington Center (UCSF-UCDC). Dr. Grudzinskas consults on the strategy and tactics of drug development, regulatory strategies and program management, and spans the full range of emerging and mature companies and is called upon frequently to assist both large and small companies prepare for FDA-sponsor meetings and FDA Advisory Committee meetings.

Dr. Grudzinskas' drug development career includes Vice President, Medications Development and Project Management, G.D. Searle and Company (now Pfizer) and Director, New Product Management at Lederle Laboratories (now Pfizer). Prior to joining Searle, Dr. Grudzinskas was the first Director of the Medications Development Division of the National Institute on Drug Abuse (NIDA) at the NIH. He is the chairman of the Curriculum Committee for the American Course in Drug Development and Regulatory Science (ACDRS). Dr. Grudzinskas is a registered U.S. Patent Agent. He received his Ph.D. from the University of Minnesota and his B.Sc. from UCLA. Dr. Grudzinskas is a member of the Board of Directors of Immunomic Therapeutics, Inc.